Volume 4, Issue 1, March 2019, Page: 7-12
"First Detection of PER-Type Extended-Spectrum β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso "
Rahimatou Yasmine Tiemtoré, Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso
Amana Mètuor-Dabiré, Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso; Department of Biochemistry-Microbiology, University of Dédougou, Dédougou, Burkina Faso
Theodora Mahoukèdè Zohoncon, Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso
Yasmine Aminata Bangré, Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso
Serge Sougue, Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso
Jacob Zongo, Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso
Jacques Simpore, Department of Biochemistry-Microbiology, University JOSEPH KI-ZERBO, Ouagadougou, Burkina Faso
Received: May 14, 2019;       Accepted: Jun. 17, 2019;       Published: Jun. 28, 2019
DOI: 10.11648/j.ijbbmb.20180401.12      View  32      Downloads  20
Abstract
Resistance to a wide variety of common antimicrobials is observed among clinical strains designated as extended-spectrum β-lactamase (ESBL) producers. They produce enzymatic proteins that effectively inactivate cephalosporins and aztreonam and are a serious global health problem that complicates treatment strategies. Many studies report a high prevalence of ESBL producers among Gram-negative bacilli. The purpose of this work was to identify of PER resistance gene in enterobacterial strains. Gram-negative bacilli resistant to at least one third-generation cephalosporin, Aztreonam or showing a synergistic image between amoxicillin + clavulanic acid and a third generation cephalosporin were isolated during an antibiogram. Antibiotic resistance was detected for the following antibiotics: Ceftriaxone, Cefotaxime, Ceftazidime and Aztreonam. A classical polymerase chain reaction (PCR) analysis of the β-lactamase PER (Pseudomonas Extended Resistance) gene was performed using specific primers in 60 ESBL-producing isolates. Among 250 strains of Gram negative bacilli collected, 60 strains (24%) showed resistance to antibiotics used. Stool samples are a major source of ESBL producers. The highest prevalence of resistant strains was observed in Escherichia coli with a rate of 35%. Among the producers of ESBL isolates, the presence of the PER gene was detected in the present study by up to 15% in 6 bacterial species. This study represents the first detection of the PER gene in Burkina Faso.
Keywords
Broad-spectrum Beta-lactamases (ESBL), PER Gene, PCR
To cite this article
Rahimatou Yasmine Tiemtoré, Amana Mètuor-Dabiré, Theodora Mahoukèdè Zohoncon, Yasmine Aminata Bangré, Serge Sougue, Jacob Zongo, Jacques Simpore, "First Detection of PER-Type Extended-Spectrum β-lactamases at Saint Camille Hospital Center of Ouagadougou, Burkina Faso ", International Journal of Biochemistry, Biophysics & Molecular Biology. Vol. 4, No. 1, 2019, pp. 7-12. doi: 10.11648/j.ijbbmb.20180401.12
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
D. L. Monnet, “Consommation d’antibiotiques et résistance bactérienne,” in Annales françaises d’anesthésie et de réanimation, 2000, vol. 19, no. 5, pp. 409–417.
[2]
A. Ouedraogo, “Prévalence, circulation et caractérisation des bactéries multirésistantes au Burkina Faso To cite this version : HAL Id : tel-01476152 Spécialité : Biologie Santé,” 2017.
[3]
E. Lecaillon et al., “Emergence de Proteus mirabilis et Klebsiella pneumoniae possédant une BLSE: traitement et suivi,” Médecine Mal. Infect., vol. 23, pp. 427–430, 1993.
[4]
P. Charlier, “Résistance bactérienne aux B-lactamines,” Medecine/Science, vol. 14, no. lipide II, pp. 544–555, 1998.
[5]
V. Cattoir, “LES NOUVELLES BETA-LACTAMASES A SPECTRE ETENDU (BLSE),” 2008.
[6]
D. Vodovar, G. Marcadé, L. Raskine, I. Malissin, and B. Mégarbane, “Entérobactéries productrices de bêta-lactamases à spectre élargi: épidémiologie, facteurs de risque et mesures de prévention,” La Rev. Médecine Interne, vol. 34, no. 11, pp. 687–693, 2013.
[7]
K. J. Zongo, A. M. Dabire, L. G. Compaore, I. Sanou, L. Sangare, and J. Simpore, “First detection of bla TEM, SHV and CTX-M among Gram negative bacilli exhibiting extended spectrum β - lactamase phenotype isolated at University Hospital Center, Yalgado Ouedraogo, Ouagadougou, Burkina,” vol. 14, no. 14, pp. 1174–1180, 2015.
[8]
V. Jarlier, M. Nicolas, G. Fournier, and A. Philippon, “Extended Broad-Spectrum ~ -Lactamases Conferring Transferable Resistance to Newer ~ -Lactam Agents in Enterobacteriaceae : Hospital Prevalence and Susceptibility Patterns,” vol. 10, no. 4, pp. 867–878, 1988.
[9]
H. Harbottle, S. Thakur, S. Zhao, and D. G. White, “Genetics of Antimicrobial Resistance,” Anim. Biotechnol., vol. 17, no. 2, pp. 111–124, Dec. 2006.
[10]
P. Boerlin and R. J. Reid-Smith, “Antimicrobial resistance: its emergence and transmission,” Anim. Heal. Res. Rev., vol. 9, no. 2, pp. 115–126, 2008.
[11]
A. Philippon and G. Arlet, “[Beta-lactamases of Gram negative bacteria: never-ending clockwork!],” Ann. Biol. Clin. (Paris)., vol. 64, no. 1, pp. 37–51, 2006.
[12]
P. Feglo et al., “Emergence of a Novel Extended-Spectrum- ␤ -Lactamase (ESBL) - Pathogenic Escherichia coli in Kumasi, Ghana,” vol. 51, no. 2, pp. 728–730, 2013.
[13]
A. Muylaert and J. G. Mainil, “Résistances bactériennes aux antibiotiques : les mécanismes et leur « contagiosité »,” pp. 109–123, 2012.
[14]
T. Kubo et al., “Corrigendum to ‘Occurrence of infection following prostate biopsy procedures in Japan : Japanese Research Group for Urinary Tract Infection (JRGU) e A multi-center retrospective study’ [J Infect Chemother 20 (2014) 232 e 237],” J. Infect. Chemother., vol. 20, no. 10, p. 660, 2014.
[15]
R. Nugent and I. N. Okeke, “Editorial When medicines fail : recommendations for curbing antibiotic resistance,” 2010.
[16]
P. Herindrainy, R. Ratovoson, and E. R. Hariniana, “Rectal Carriage of Extended-Spectrum Beta-Lactamase-Producing Gram- Rectal Carriage of Extended-Spectrum Beta-Lactamase- Producing Gram-Negative Bacilli in Community Settings in Madagascar,” no. November 2017, pp. 8–10, 2011.
[17]
S. Sirinavin and S. F. Dowell, “Antimicrobial resistance in countries with limited resources: unique challenges and limited alternatives,” Semin. Pediatr. Infect. Dis., vol. 15, no. 2, pp. 94–98, 2004.
[18]
J. G. Pieboji, “CARACTÉRISATION DES BETA-LACTAMASES ET LEUR INHIBITION PAR LES EXTRAITS DE PLANTES MÉDICINALES,” 2007.
[19]
C. Zhuo, X. Li, Z. Zong, and N. Zhong, “Epidemic Plasmid Carrying bla CTX-M-15 in Klebsiella penumoniae in China,” vol. 8, no. 1, pp. 1–8, 2013.
[20]
A. Mètuor-dabiré, “Caractérisations moléculaire et cinétique des types de β-lactamases à spectre élargi (BLSE) de souches bactériennes collectées au Centre Hospitalier Universitaire Pédiatrique Charles De Gaulle (CHUP-CDG) de Ouagadougou,” Thèse Présentée pour obtenir le grade Docteur l ’ Univ. Ouagadougou, 2014.
[21]
P. Nordmann, E. Ronco, T. Naas, C. Duport, Y. Michel-Briand, and R. Labia, “Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa,” Antimicrob. Agents Chemother., vol. 37, no. 5, pp. 962–969, May 1993.
[22]
P. Nordmannl, T. Naas, S. De Microbiologie, H. R. Poincare, and F. D. M. Paris-ouest, “Sequence Analysis of PER-1 Extended-Spectrum Comparison with Class A 13-Lactamases,” vol. 38, no. 1, pp. 104–114, 1994.
[23]
H. Vahaboglu et al., “Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study,” Antimicrob. Agents Chemother., vol. 41, no. 10, pp. 2265–2269, Oct. 1997.
[24]
G. Bahar, B. Eraç, A. Mert, and Z. Gülay, “PER-1 Production in a Urinary Isolate of Providencia rettgeri,” J. Chemother., vol. 16, no. 4, pp. 343–346, Aug. 2004.
[25]
D. Yong et al., “High prevalence of PER-1 extended-spectrum beta-lactamase-producing Acinetobacter spp. in Korea,” Antimicrob. Agents Chemother., vol. 47, no. 5, pp. 1749–1751, May 2003.
[26]
L. Pagani et al., “Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy,” J. Clin. Microbiol., vol. 42, no. 6, pp. 2523–2529, Jun. 2004.
[27]
M. PEREIRA et al., “PER-1 Extended-Spectrum β-Lactamase Production in an Alcaligenes faecalis Clinical Isolate Resistant to Expanded-Spectrum Cephalosporins and Monobactams from a Hospital in Northern Italy,” Microb. Drug Resist. vol. 6, no. 1, pp. 85–90, Jan. 2000.
Browse journals by subject